Hohl Benjamin 4
4 · Enliven Therapeutics, Inc. · Filed Jul 30, 2025
Insider Transaction Report
Form 4
Hohl Benjamin
CHIEF FINANCIAL OFFICER
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2025-07-28−3,250→ 111,556 totalExercise: $2.48Exp: 2031-08-02→ Common Stock (3,250 underlying) - Exercise/Conversion
Common Stock
2025-07-28$2.48/sh+3,250$8,060→ 26,250 total - Sale
Common Stock
2025-07-28$21.30/sh−65$1,385→ 23,000 total - Sale
Common Stock
2025-07-28$20.45/sh−3,185$65,119→ 23,065 total
Footnotes (4)
- [F1]The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $20.09 to $21.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]This transaction was executed in multiple trades at prices ranging from $21.1377 to $21.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F4]All of the shares subject to this option are fully vested and exercisable as of the date hereof.